Kymab Limited

Volker Germaschewski

Ian Kirby

Jamie Iain Campbell

Miha Kosmac

Stephen D Gillies

Cassandra Van Krinks

Thomas Gallagher

Nikole Sandy

E-Chiang Lee

Stephen John Arkinstall

Steve Arkinstall

Matthew John McCourt

Richard Charles Alfred Sainson

Mohammed Hanif Ali

Cecilia Deantonio

Jasper Clube

Joana De Abreu Carvalho

Nahida Parveen

Hanif Ali

Gwenoline Borhis

Rachael Jane Kimber

Martin Yateman

Igor Theurl

Robert Rowlands

Nikole Sandy Nee Waddell

The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

Anti-PD-L1 antibodies

Anti-PD-L1 and IL-2 cytokines

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Anti-ICOS antibodies

The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.

Methods, regimens, combinations and antagonists

The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo

The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides. The present invention relates to multivalent (eg, multispecific) antibodies, antibody chains and polypeptides, as well as heavy chain-only antibodies (H2 antibodies) that are devoid of light chains. The invention further relates to the selection, maturation and production of these in vivo in non-human vertebrates and non-human vertebrate cells. To this end the invention also relates to such non-human vertebrates and cells. The invention also relates to the provision of means to produce and select heavy chain-only antibodies and heavy chains comprising variable domains that have undergone affinity maturation.

Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins

Antibodies and immunocytokines

Growing community of inventors

Cambridge, United Kingdom

Volker Germaschewski